Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The MLL-Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.
Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, Krippner-Heidenreich A, Grebien F, McGeehan G, Zwaan CM, Heidenreich O. Rasouli M, et al. Among authors: zwaan cm. Hemasphere. 2023 Jul 27;7(8):e935. doi: 10.1097/HS9.0000000000000935. eCollection 2023 Aug. Hemasphere. 2023. PMID: 37520776 Free PMC article.
Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors.
Barajas JM, Rasouli M, Umeda M, Hiltenbrand R, Abdelhamed S, Mohnani R, Arthur B, Westover T, Thomas ME 3rd, Ashtiani M, Janke LJ, Xu B, Chang TC, Rosikiewicz W, Xiong E, Rolle C, Low J, Krishan R, Song G, Walsh MP, Ma J, Rubnitz JE, Iacobucci I, Chen T, Krippner-Heidenreich A, Zwaan CM, Heidenreich O, Klco JM. Barajas JM, et al. Among authors: zwaan cm. Blood. 2024 Feb 15;143(7):619-630. doi: 10.1182/blood.2023021359. Blood. 2024. PMID: 37890156 Free PMC article.
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study.
Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Patterson BC, Samis J, Izquierdo M, Titorenko K, Li S, Sosothikul D. Hijiya N, et al. Among authors: zwaan cm. Blood Adv. 2023 Dec 12;7(23):7279-7289. doi: 10.1182/bloodadvances.2023010122. Blood Adv. 2023. PMID: 37738125 Free PMC article.
AcSé-ESMART, a European precision cancer medicine proof-of-concept platform trial.
Geoerger B, Paoletti X, Bautista F, Gatz SA, Marshall LV, André N, Berlanga P, Ducassou S, Pasqualini C, Casanova M, Zwaan CM, Nysom K, Rubino J, Goff DV, Archambaud B, Abbou S, Schleiermacher G, Dufour C, Blanc P, Hoog-Labouret N, Buzyn A, Vassal G. Geoerger B, et al. Among authors: zwaan cm. Nat Med. 2023 Dec;29(12):2985-2987. doi: 10.1038/s41591-023-02580-5. Nat Med. 2023. PMID: 37857712 No abstract available.
Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer.
Bautista F, Verdú-Amorós J, Geoerger B, Rubio-San-Simón A, Paoletti X, Zwaan CM, Casanova M, Marshall LV, Carceller F, Doz F, Lecinse C, Vassal G, Pearson ADJ, Kearns P, Moreno L; Innovative Therapies For Children With Cancer Consortium. Bautista F, et al. Among authors: zwaan cm. J Clin Oncol. 2024 May 14:JCO2301237. doi: 10.1200/JCO.23.01237. Online ahead of print. J Clin Oncol. 2024. PMID: 38743911
307 results